JP Morgan 2026: AbbVie Advances its Pipeline

Top executives from AbbVie took the stage at the 44^th annual JP Morgan Healthcare Conference in San Francisco on Wednesday morning to discuss the company’s current situation, along with its plans for growth in the coming years.¹

As has been the case with the other major pharma companies, AbbVie is focused on expanding and diversifying its pipeline ahead of the coming patent cliff.

Chief commercial officer Jeffrey R. Stewart and chief scientific officer Roopal Thakkar, MD, joined chief financial officer Scott Reents on stage to answer questions. In response to a question about the company’s priorities, Reents answered, “When we look at 2026, it’s a continuation of the strategy that we’ve been articulating. One is to execute operationally in a way that delivers strong financial results. Second, to advance our pipeline.”

He continued, “When we think about the momentum of the business and our results, certainly there was a lot of uncertainty going into Humira. We’re happy with how that played out as an organization. When we look at the 2025 guidance, that’s reaching peak sales following the LOE. If you rewind back to 2023, we’ve grown in $7 billion in the aggregate. That includes absorbing $10 billion in Humira erosion and $2 billion from the IRA. That came from our growth platform.”

When it came time to discuss the 2025 results, Reents explained, “our business grew about 8% on the topline. Our growth platform grew approximately 19%. We have strong momentum and continuing that as we drive towards our long-term guidance is a big part. Of course, developing our growth drivers for the next decade. We have to advance that pipeline and we expect some big approvals in the next two years. We also have indication expansion coming for several drugs. Looking at that overall portfolio, we going to continue to advance that pipeline.”

Prior to the presentation, AbbVie announced a deal with the Trump administration to provide low-prices to Medicaid while also pledging $100 billion in US-based R&D.²

In a press release, CEO Robert A. Michael said, “AbbVie's mission is to make a remarkable impact for the patients we serve around the world through our innovative medicines," said Robert A. Michael, chairman and chief executive officer, AbbVie. "With approximately 29,000 U.S.-based employees and products treating 16 million Americans annually, we understand the complexity and access challenges in our healthcare system. AbbVie is following President Trump's call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation. Thank you to President Trump and his team for their leadership to help deliver cost savings and supporting our efforts to deliver innovative treatments for American patients."

At the same time, AbbVie also announced plans to acquire a manufacturing facility in Arizona for about $175 million, with plans to employ 200 workers at the site.³

"Over the next decade, AbbVie is investing more than $10 billion in capital to broadly support innovation and expand our manufacturing capabilities and capacity in the U.S.," Michael said in a press release. “With this investment, AbbVie is strengthening our manufacturing capabilities, ensuring we are well-positioned to develop and deliver next-generation medicines that make a remarkable impact on patients' lives."

AbbVie also made a third announcement, revealing an exclusive licensing agreement with RegeGen to develop a novel bispecific antibody for advanced solid tumors.⁴

"Our partnership with RemeGen reflects AbbVie's commitment to not only advance novel oncology treatments, but also to build strong collaborations with biopharmaceutical innovators globally as an increasingly important source of scientific and clinical progress," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology at AbbVie. "By combining the immune checkpoint inhibition and anti-angiogenic activity of RC148 together with the targeted cytotoxic activity of ADCs, we have the potential to identify meaningful options for patients across a range of solid tumors."

In the same press release, RemeGen chief executive officer Dr. Jianmin Fang added, "This collaboration is a significant milestone for RemeGen, highlighting the innovative potential of RC148 in addressing critical unmet medical needs in cancer treatment. The deal further underscores RemeGen's commitment to bringing cutting-edge therapies to patients worldwide. Working with AbbVie, we look forward to maximizing RC148's clinical and commercial potential in China and globally."

Sources

1. AbbVie JP Morgan Healthcare Conference Webcast. AbbVie. January 14, 2026. https://jpmorgan.metameetings.net/events/healthcare26/sessions/317208-abbvie-inc/webcast?gpu_only=true&kiosk=true
2. AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans. AbbVie. January 12, 2026. https://news.abbvie.com/2026-01-12-AbbVie-and-Trump-Administration-Reach-Agreement-to-Improve-Access-and-Affordability-for-Americans
3. AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States. AbbVie. January 12, 2026. https://news.abbvie.com/2026-01-12-AbbVie-to-Acquire-Arizona-Manufacturing-Facility,-Further-Strengthening-Manufacturing-Capabilities-in-the-United-States
4. AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors. AbbVie. January 12, 2026. https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors